scispace - formally typeset
Open AccessJournal ArticleDOI

Conjunctival Melanomas Harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas

Reads0
Chats0
TLDR
The presence of NRAS or BRAF mutations in a mutually exclusive pattern in roughly half (47%) of conjunctival melanomas and the pattern of CNAs argue for conjunctive melanoma being closely related to cutaneous and mucosal melanoma but entirely distinct from uveal melanoma.
Abstract
Purpose: Conjunctival melanoma is a rare but potentially deadly tumor of the eye. Despite effective local therapies, recurrence and metastasis remain frequent. Once the tumor has metastasized, treatment options are limited and the prognosis is poor. To date, little is known of the genetic alterations in conjunctival melanomas. Experimental Design: We conducted genetic analysis of 78 conjunctival melanomas, to our knowledge the largest cohort reported to date. An oncogene hotspot array was run on 38 samples, screening for a panel of known cancer-relevant mutations. Thirty tumors were analyzed for genome-wide copy number alterations (CNA) using array-based comparative genomic hybridization. Sanger sequencing of selected target mutations was conducted in all samples. Results: BRAF mutations were identified in 23 of 78 (29%) tumors. NRAS mutations, previously not recognized as relevant in conjunctival melanoma, were detected in 14 of 78 (18%) tumors. We found CNAs affecting various chromosomes distributed across the genome in a pattern reminiscent of cutaneous and mucosal melanoma but differing markedly from uveal melanoma. Conclusions: The presence of NRAS or BRAF mutations in a mutually exclusive pattern in roughly half (47%) of conjunctival melanomas and the pattern of CNAs argue for conjunctival melanoma being closely related to cutaneous and mucosal melanoma but entirely distinct from uveal melanoma. Patients with metastatic conjunctival melanoma should be considered for therapeutic modalities available for metastatic cutaneous and mucosal melanoma including clinical trials of novel agents. Clin Cancer Res; 19(12); 3143–52. ©2013 AACR .

read more

Citations
More filters
Journal ArticleDOI

CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects.

TL;DR: In this paper, a literature review was performed using a PubMed search for publications between 1990 and 2017 to review immune checkpoint inhibitor indications and ophthalmic side effects, using three ligand-specific inhibitors.
Journal ArticleDOI

TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma

TL;DR: UV-induced Tert promoter mutations are one of the most frequent genetic alterations in melanoma, with frequencies varying depending on melanoma subtype, and in nonacral cutaneous melanomas, presence of TERT promoter mutations is independently associated with poor prognosis.
Journal ArticleDOI

Pathways and therapeutic targets in melanoma

TL;DR: This review aims to summarize the current knowledge of molecular pathways and their clinical relevance in melanoma and focuses on understanding and overcoming resistance to targeted therapies, and understanding the underlying causes of the heterogeneous responses to immune therapy.
Journal ArticleDOI

Targeted therapy in cancer

TL;DR: The application of discoveries in cancer biology in clinic holds the promise to improve the clinical outcomes in a large scale of patients with cancer and will expedite the development of anticancer drugs and will accelerate the implementation of precision medicine.
Journal ArticleDOI

The biology of uveal melanoma

TL;DR: Current knowledge of the biology of UM is reviewed, several lines of evidence indicate that inflammation and macrophages play a pro-tumor role in UM and in its hepatic metastases, and recent approaches to UM treatment are discussed.
References
More filters
Journal ArticleDOI

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

Rafael Lozano, +195 more
- 15 Dec 2012 - 
TL;DR: The Global Burden of Diseases, Injuries, and Risk Factors Study 2010 aimed to estimate annual deaths for the world and 21 regions between 1980 and 2010 for 235 causes, with uncertainty intervals (UIs), separately by age and sex, using the Cause of Death Ensemble model.
Journal ArticleDOI

Cancer statistics, 2012

TL;DR: The reduction in overall cancer death rates since 1990 in men and 1991 in women translates to the avoidance of about 1,024,400 deaths from cancer, which can be accelerated by applying existing cancer control knowledge across all segments of the population, with an emphasis on those groups in the lowest socioeconomic bracket.
Related Papers (5)